Shire To Pay $4.2 Billion For Rare Disease Firm ViroPharma Incorporated
London-listed Shire is buying ViroPharma for $4.2 billion, its biggest deal yet to strengthen its portfolio of lucrative drugs to treat rare diseases, which are attracting increasing attention from drugs companies as patents expire on their older treatments. Several companies including France's Sanofi, according to reports, were interested in ViroPharma, which makes Cinryze for the treatment of immune disorder hereditary angioedema. Treatments for such rare disorders can command huge prices, running into hundreds of thousands of dollars a year per patient.
Help employers find you! Check out all the jobs and post your resume.